Related Experiment Video
Updated: Apr 5, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
12.8K
Primary refractory diffuse large B cell lymphoma in the rituximab era.
Clémentine Sarkozy1, Bertrand Coiffier
1Hospices Civils de Lyon, Service d'Hématologie, Pierre Bénite, France.
Current Opinion in Oncology
|August 11, 2015
Summary
Primary refractory diffuse large B cell lymphoma (DLBCL) remains a challenge despite rituximab. New markers and therapies are needed for these poor-prognosis patients, who represent 20% of cases.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Diffuse large B cell lymphoma (DLBCL) treatment has improved with rituximab and chemotherapy.
- However, a significant subset of patients with primary refractory DLBCL still face poor outcomes.
Purpose of the Study:
- To review the outcomes of primary refractory DLBCL in the rituximab era.
- To discuss therapeutic options and novel biological markers for early identification.
Main Methods:
- Literature review of studies on primary refractory DLBCL.
- Analysis of treatment outcomes and prognostic markers.
Main Results:
- Rituximab has improved overall DLBCL outcomes, but primary refractory cases persist.
- Primary refractory DLBCL accounts for 20% of cases with very poor survival.
- These patients often progress during first-line therapy or relapse within a year.
Conclusions:
- Patients achieving remission and disease-free for 2 years have outcomes similar to healthy individuals.
- Primary refractory DLBCL remains an unmet medical need requiring novel therapeutic strategies.
- Identifying predictive biomarkers is crucial for distinguishing these cases at diagnosis.
